Cargando…

Chasing Immune Checkpoint Inhibitors in Ovarian Cancer: Novel Combinations and Biomarker Discovery

SIMPLE SUMMARY: Immune checkpoint inhibitors (ICIs) have been investigated in epithelial ovarian cancer in first-line and recurrent settings. When used as a single agent or in combination with chemotherapy, they have largely failed to improve patients’ outcome and thus, have not entered routine use...

Descripción completa

Detalles Bibliográficos
Autores principales:	Colombo, Ilaria, Karakasis, Katherine, Suku, Sneha, Oza, Amit M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10296292/ https://www.ncbi.nlm.nih.gov/pubmed/37370830 http://dx.doi.org/10.3390/cancers15123220

Ejemplares similares

Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer
por: McMullen, Michelle, et al.
Publicado: (2020)

Measuring Quality of Life in Ovarian Cancer Clinical Trials—Can We Improve Objectivity and Cross Trial Comparisons?
por: Bhat, Gita, et al.
Publicado: (2020)

Ovarian cancer treatment: The end of empiricism?
por: Lheureux, Stephanie, et al.
Publicado: (2015)

Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer
por: Colombo, Ilaria, et al.
Publicado: (2018)

Ovarian Cancer and BRCA1/2 Testing: Opportunities to Improve Clinical Care and Disease Prevention
por: Karakasis, Katherine, et al.
Publicado: (2016)

DUETTE: a phase II randomized, multicenter study to investigate the efficacy and tolerability of a second maintenance treatment in patients with platinum-sensitive relapsed epithelial ovarian cancer, who have previously received poly(ADP-ribose) polymerase (PARP) inhibitor maintenance treatment
por: McMullen, Michelle, et al.
Publicado: (2020)

Antibiotic Discovery and Resistance: The Chase and the Race
por: Iskandar, Katia, et al.
Publicado: (2022)

Angiogenesis Inhibitors as Anti-Cancer Therapy Following Renal Transplantation: A Case Report and Review of the Literature
por: Kasherman, Lawrence, et al.
Publicado: (2021)

The Chase Metallic Combination Plate
Publicado: (1890)

Updates on systemic therapy for cervical cancer
por: Gopu, Paul, et al.
Publicado: (2021)

Immune cell profiling in the age of immune checkpoint inhibitors: implications for biomarker discovery and understanding of resistance mechanisms
por: Lim, Su Yin, et al.
Publicado: (2018)

Immune Checkpoint Inhibitors in Lung Cancer: Role of Biomarkers and Combination Therapies
por: Maung, Tun Zan, et al.
Publicado: (2020)

To chase or not to chase: A study on the role of mentalization and alcohol consumption in chasing behavior
por: Nigro, Giovanna, et al.
Publicado: (2019)

Biomarkers for Immune Checkpoint Inhibitors in Melanoma
por: Kitano, Shigehisa, et al.
Publicado: (2018)

Can TP53 variant negative be high-grade serous ovarian carcinoma? A case series
por: Kasherman, Lawrence, et al.
Publicado: (2021)

How to use immune checkpoint inhibitor in ovarian cancer?
por: Park, Junsik, et al.
Publicado: (2019)

Immune-Checkpoint Inhibitors in Platinum-Resistant Ovarian Cancer
por: Indini, Alice, et al.
Publicado: (2021)

Biomarkers for predicting the efficacy of immune checkpoint inhibitors
por: Wang, Chengji, et al.
Publicado: (2022)

Biomarkers of therapeutic response with immune checkpoint inhibitors
por: Bindal, Poorva, et al.
Publicado: (2021)

Radiation Biomarkers: Silver Bullet, or Wild Goose Chase?
por: Rutten, Eric Andreas, et al.
Publicado: (2021)

Chasing Carbon
Publicado: (2020)

Adoptive cell therapy in combination with checkpoint inhibitors in ovarian cancer
por: Kverneland, Anders Handrup, et al.
Publicado: (2020)

Immune checkpoint inhibitors: recent progress and potential biomarkers
por: Darvin, Pramod, et al.
Publicado: (2018)

Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities
por: Xu, Ya, et al.
Publicado: (2020)

Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
por: Bai, Rilan, et al.
Publicado: (2020)

Molecular imaging biomarkers for immune checkpoint inhibitor therapy
por: van de Donk, Pim P, et al.
Publicado: (2020)

Peripheral Blood-Based Biomarkers for Immune Checkpoint Inhibitors
por: An, Ho Jung, et al.
Publicado: (2021)

Biomarkers for response to immune checkpoint inhibitors in gastrointestinal cancers
por: Li, Meng, et al.
Publicado: (2022)

Biomarkers for Immune Checkpoint Inhibitors in Renal Cell Carcinoma
por: Martin, Spencer D., et al.
Publicado: (2023)

Pursuit tracks chase: exploring the role of eye movements in the detection of chasing
por: Šimkovic, Matúš, et al.
Publicado: (2015)

Biomarkers in sepsis-looking for the Holy Grail or chasing a mirage!
por: Ahuja, Neelmani, et al.
Publicado: (2023)

OSQAR-CHASE Proposal
por: (Pugnat, P, et al.
Publicado: (2015)

Chasing Hot Molecules
por: Webb, Sarah
Publicado: (2016)

Chasing Ecological Interactions
por: Jordano, Pedro
Publicado: (2016)

Chasing viruses feverishly
por: Lahariya, Chandrakant
Publicado: (2017)

Dr. Henry S. Chase
Publicado: (1898)

Immune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer?
por: Mittica, Gloria, et al.
Publicado: (2016)

Immune checkpoint inhibitors in ovarian cancer: where do we stand?
por: Leary, Alexandra, et al.
Publicado: (2021)

Current Understanding on Why Ovarian Cancer Is Resistant to Immune Checkpoint Inhibitors
por: Pawłowska, Anna, et al.
Publicado: (2023)

Abscopal effect of radiotherapy combined with immune checkpoint inhibitors
por: Liu, Yang, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_e1mq8rd5fa1ve4fiqesltsgtf9